Zibotentan Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Zibotentan comprises 10 peer-reviewed publications across 10 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Renal Insufficiency, Chronic, Angina Pectoris, Kidney Diseases, and Renal Insufficiency. Most recent publication: Exercise treadmill testing for efficacy evaluation in randomized, controlled trials., Am Heart J, 2026.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.Stern EP, Host LV, Wanjiku I, et al. · Arthritis Res Ther · 2022
- Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.Smeijer JD, Wasehuus VS, Dhaun N, et al. · J Am Soc Nephrol · 2024
- Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.Morrow A, Young R, Abraham GR, et al. · Am Heart J · 2026
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.Morrow A, Young R, Abraham GR, et al. · Circulation · 2024
- Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.Mercier AK, Sunnåker M, Ueckert S, et al. · Clin Pharmacokinet · 2023
- Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.Hu S, Lee K, He JC, et al. · Clin J Am Soc Nephrol · 2026
- Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.Heerspink HJL, Kiyosue A, Wheeler DC, et al. · Lancet · 2023
- Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.Heerspink HJL, Greasley PJ, Ahlström C, et al. · Nephrol Dial Transplant · 2024
Publications by year
2013–2026: 10 publications.
2013
1
2021
1
2022
1
2023
2
2024
3
2026
2
Publications by indication
Renal Insufficiency, Chronic (5)
- Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.
- Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
- Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
- Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.
- Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Angina Pectoris (2)
- Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.
Kidney Diseases (1)
- Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
Renal Insufficiency (1)
- Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
Hypersensitivity (1)
- A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Publications by journal
- Arthritis Res Ther1 paper
- J Am Soc Nephrol1 paper
- Curr Opin Nephrol Hypertens1 paper
- Am Heart J1 paper
- Circulation1 paper
- Clin Pharmacokinet1 paper
- Clin J Am Soc Nephrol1 paper
- Lancet1 paper
- Nephrol Dial Transplant1 paper
- Gynecol Oncol1 paper
All Zibotentan publications (10)
2026 (2 papers)
- Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.Morrow A, Young R, Abraham GR, et al. · Am Heart J · 2026 · Derived
- Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.Hu S, Lee K, He JC, et al. · Clin J Am Soc Nephrol · 2026 · Derived
2024 (3 papers)
- Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.Smeijer JD, Wasehuus VS, Dhaun N, et al. · J Am Soc Nephrol · 2024 · Derived
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.Morrow A, Young R, Abraham GR, et al. · Circulation · 2024 · Derived
- Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.Heerspink HJL, Greasley PJ, Ahlström C, et al. · Nephrol Dial Transplant · 2024 · Derived
2023 (2 papers)
- Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.Mercier AK, Sunnåker M, Ueckert S, et al. · Clin Pharmacokinet · 2023 · Derived
- Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.Heerspink HJL, Kiyosue A, Wheeler DC, et al. · Lancet · 2023 · Derived
2022 (1 paper)
- Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.Stern EP, Host LV, Wanjiku I, et al. · Arthritis Res Ther · 2022 · Derived
2021 (1 paper)
- Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.Smeijer JD, Kohan DE, Webb DJ, et al. · Curr Opin Nephrol Hypertens · 2021 · Derived
2013 (1 paper)
- A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).Cognetti F, Bagnato A, Colombo N, et al. · Gynecol Oncol · 2013 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 26 May 2026 18:00:23 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).